Alydar Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Alydar Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$5.71M	Buy	+220,000	New	+$4.03M	3.1%	8

Other funds holding HZNP

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Alydar Partners's HZNP Position: Q1 2015 in Review

Alydar Partners opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2015: 220,000 shares worth $5.71M. The stake represents 3.1% of the portfolio and ranks #8 among its holdings.

177 funds tracked by Wall St. Rank hold HZNP as of Q1 2015.

Alydar Partners held 220,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.71M as of Q1 2015.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Alydar Partners position in Q1 2015.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 3.1% of Alydar Partners's portfolio in Q1 2015, its #8 holding.
177 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2015.

Based on Alydar Partners's 13F filing for Q1 2015, filed 15 May 2015.